Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?
- Design
- Mendelian randomization · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclear[Auto] Population characteristics not extractable from abstract (age/BMI not reported in abstract). Needs manual review.
- Could weight loss explain it?
- Unknown[Auto] Harm signal; weight-loss mediation not the relevant question, but consider whether harms relate to rapid weight loss or reduced intake.
- Study tier
- Preliminary[Auto] Not peer reviewed (preprint, abstract or registration). Early-warning only.
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 20, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75. This item has not been peer reviewed.
[Auto, unreviewed; last sentences of abstract] These anomalies were complemented by GLP1R-targeted MR evidence: no causal effect of genetically proxied GLP1R activation (all P [≥] 0.11), while confirming glucose-lowering (P = 7.6E-6). ConclusionsPharmacovigilance and genetic evidence converge to show that the semaglutide-NAION signal reflects notoriety bias rather than toxicity.
01Findings
What the study reported
- Drugs
- Semaglutide
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
Study quality details
- Study design
- Mendelian randomization
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- hard
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- UNKNOWN
- Statistical precision
- CI reported: 95% CI 106
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- no
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- not available in metadata
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
ObjectiveTo determine whether the semaglutide-NAION association reflects true toxicity or reporting bias. Research design and methodsWe performed temporal disproportionality analysis of FDA Adverse Event Reporting System (FAERS) data (2018Q1-2026Q2) to detect reporting anomalies and class-level spillover, and GLP1R cis-eQTL drug-target Mendelian randomization (MR) of NAION-relevant ocular phenotypes to test causal effects of GLP1R activation on semaglutide-relevant ocular toxicity. ResultsSemaglutide ROR was 116.8 (95% CI 106.8-127.7). FAERS rates rose from below 8 per 10,000 annually (2018-2023) to 52 (2024), 177 (2025), and 203 (2026H1) after July 2024 publication, while comparators remained stable. Median time to onset was 246 days (Weibull {beta} = 1.09), a random-type profile inconsistent with cumulative toxicity. These anomalies were complemented by GLP1R-targeted MR evidence: no causal effect of genetically proxied GLP1R activation (all P [≥] 0.11), while confirming glucose-lowering (P = 7.6E-6). ConclusionsPharmacovigilance and genetic evidence converge to show that the semaglutide-NAION signal reflects notoriety bias rather than toxicity.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| medrxiv:medrxiv | Sep 20, 2026 | 10.64898/2026.09.06.26362369 first ingestion |